TY - JOUR
T1 - Comparative sensitivities between different plasma B-type natriuretic peptide assays in patients with minimally symptomatic heart failure
AU - Tang, W. H.Wilson
AU - Philip, Kiran
AU - Hazen, Stanley L.
AU - Stevenson, Cindy E.
AU - Pepoy, Michael
AU - Neale, Sarah
AU - Francis, Gary S.
AU - Van Lente, Frederick
AU - Smith, Andrew
AU - Wu, Alan H.B.
PY - 2005
Y1 - 2005
N2 - Plasma B-type natriuretic peptide (BNP) assays have become widely used to diagnose and manage patients with heart failure. However, differences in assay characteristics may have important implications when BNP is used as a screening test for heart failure at a specific cutoff value. We performed a prospective comparison of 2 commercially available assays - one that is a laboratory-based, microparticle enzyme immunoassay (MEIA) that uses EDTA plasma specimens and one that is a point-of-care (POC), single-use fluorescence immunoassay that uses EDTA-anticoagulated whole blood or plasma specimens - in patients with heart failure and healthy controls. Despite the overall concordance between different SNP assays for the diagnosis of heart failure, their sensitivities may differ when compared at the approved diagnostic cutoff value of 100 pg/mL. At this cutoff value, the MEIA on AxSYM® demonstrated greater sensitivity than POC Triage® BNP assay in minimally symptomatic patients with heart failure. Therefore, for screening purposes, cutoff values for plasma BNP or N-terminal pro-BNP levels should be specific for each assay to optimize test performance. These findings suggest that there is a relationship between the decision statistics used in screening for left ventricular dysfunction and the type of diagnostic assay used.
AB - Plasma B-type natriuretic peptide (BNP) assays have become widely used to diagnose and manage patients with heart failure. However, differences in assay characteristics may have important implications when BNP is used as a screening test for heart failure at a specific cutoff value. We performed a prospective comparison of 2 commercially available assays - one that is a laboratory-based, microparticle enzyme immunoassay (MEIA) that uses EDTA plasma specimens and one that is a point-of-care (POC), single-use fluorescence immunoassay that uses EDTA-anticoagulated whole blood or plasma specimens - in patients with heart failure and healthy controls. Despite the overall concordance between different SNP assays for the diagnosis of heart failure, their sensitivities may differ when compared at the approved diagnostic cutoff value of 100 pg/mL. At this cutoff value, the MEIA on AxSYM® demonstrated greater sensitivity than POC Triage® BNP assay in minimally symptomatic patients with heart failure. Therefore, for screening purposes, cutoff values for plasma BNP or N-terminal pro-BNP levels should be specific for each assay to optimize test performance. These findings suggest that there is a relationship between the decision statistics used in screening for left ventricular dysfunction and the type of diagnostic assay used.
UR - http://www.scopus.com/inward/record.url?scp=20844445440&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20844445440&partnerID=8YFLogxK
U2 - 10.1016/S1098-3597(05)80010-9
DO - 10.1016/S1098-3597(05)80010-9
M3 - Article
C2 - 15899365
AN - SCOPUS:20844445440
SN - 1098-3597
VL - 7
SP - S18-S24
JO - Clinical Cornerstone
JF - Clinical Cornerstone
IS - SUPPL. 1
ER -
